International multiple sclerosis conference features 35 new studies
using Simoa technology demonstrating potential of Neurofilament light
chain (NfL) as a reliable and sensitive disease biomarker
LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix
Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis
to advance the science of precision health, today announced that its
ultra-sensitive Simoa technology has been highlighted in 35 new research
studies to be presented at the 34th
Congress of the European Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS), from Oct. 10-12, 2018 in Berlin,
Germany. This year’s program marks a notable increase in applications
for Simoa as it applies to the study of Neurofilament light chain (NfL),
providing further validation of its utility as a transformative
biomarker for multiple sclerosis (MS).
“Like many neurodegenerative conditions, Multiple Sclerosis is difficult
to diagnose objectively and disease progression is determined primarily
by imaging and symptoms reported,” said Kevin Hrusovsky, CEO, President
and Chairman of Quanterix and Founder of Powering Precision Health. “We
are very encouraged by the rapidly growing body of scientific research
demonstrating that NfL, which could never be measured in blood before
our Simoa technology was introduced, could be a crucial biomarker in
diagnosing MS and monitoring treatment effectiveness.”
MS is among the most prevalent neurodegenerative conditions affecting
individuals between the ages of 20 and 50 years old. The National
Multiple Sclerosis Society estimates that more than 2.3 million
people are impacted by the disease worldwide. With no single test
capable of identifying the condition, diagnoses can easily be missed,
delayed or inaccurate, suggesting this figure may be even higher.
Sessions featuring Quanterix’ Simoa technology at ECTRIMS 2018 will
explore blood-based NfL’s correlation with MS and assess the biomarker’s
reliability compared to traditional cerebral spinal fluid (CSF)
alternatives in both adult and pediatric MS. This year’s program boasts
a 250 percent increase in Simoa-powered research for the study of NfL in
MS compared to last year’s program and a more than 400 percent increase
compared to the 2016 conference. Research spanning these three
consecutive years, which totals nearly 50 peer-reviewed studies,
substantiates Simoa as a critical technology for the detection and
analysis of NfL in blood. Presentations and posters at this year’s
ECTRIMS add to a growing body of research supporting Simoa’s
potential to detect and quantify NfL for a variety of neurodegenerative
Quanterix will also feature the poster session (P539), “International
multi-site analytical validation of the Simoa NF-light assay in human
serum samples from multiple sclerosis patients,” on display on Oct.
10 during Poster Session I. The Company will be demonstrating its SR-XTM
platform, which offers high-powered biomarker detection and an extensive
menu of assays in a compact and affordable system.
Quanterix welcomes attendees to register
for a cocktail networking reception on Oct. 11 from 5-8 p.m. (local
time) at the Sofitel Berlin Kurfürstendamm hotel.
To learn more about Quanterix and its biomarker detection solutions,
visit ECTRIMS Booth C17.
To learn more about Quanterix’ NfL assay, click
Quanterix is a company that’s digitizing
biomarker analysis with the goal of advancing the science of precision
health. The company’s digital health solution, Simoa, has the potential
to change the way in which healthcare is provided today by giving
researchers the ability to closely examine the continuum from health to
disease through ultrasensitive detection of biomarkers and to accelerate
drug development and approval. Quanterix’ technology is designed to
enable much earlier disease detection, better prognoses and enhanced
treatment methods to improve the quality of life and longevity of the
population for generations to come. The technology is currently being
used for research applications in several therapeutic areas, including
oncology, neurology, cardiology, immunology and infectious disease. The
company was established in 2007 and is located in Lexington,
Massachusetts. For additional Information, please visit https://www.quanterix.com.
This press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,”
“plan,” “anticipate,” “estimate,” “intend” and similar expressions (as
well as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on Quanterix’
expectations and assumptions as of the date of this press release. Each
of these forward-looking statements involves risks and uncertainties.
Factors that may cause Quanterix’ actual results to differ from those
expressed or implied in the forward-looking statements in this press
release are discussed in Quanterix’ filings with the U.S. Securities and
Exchange Commission, including the “Risk Factors” sections contained
therein. Except as required by law, Quanterix assumes no obligation to
update any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes available.
Lindsay Poole, 617-502-4300